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Abstract
Background: Curcumin (diferuloylmethane), the yellow pigment in the Asian spice turmeric, is a hydrophobic
polyphenol from the rhizome of Curcuma longa. Because of its chemopreventive and chemotherapeutic potential
with no discernable side effects, it has become one of the major natural agents being developed for cancer
therapy. Accumulating evidence suggests that curcumin induces cell death through activation of apoptotic
pathways and inhibition of cell growth and proliferation. The mitotic checkpoint, or spindle assembly checkpoint
(SAC), is the major cell cycle control mechanism to delay the onset of anaphase during mitosis. One of the key
regulators of the SAC is the anaphase promoting complex/cyclosome (APC/C) which ubiquitinates cyclin B and
securin and targets them for proteolysis. Because APC/C not only ensures cell cycle arrest upon spindle disruption
but also promotes cell death in response to prolonged mitotic arrest, it has become an attractive drug target in
cancer therapy.
Methods: Cell cycle profiles were determined in control and curcumin-treated medulloblastoma and various other
cancer cell lines. Pull-down assays were used to confirm curcumin binding. APC/C activity was determined using
an in vitro APC activity assay.
Results: We identified Cdc27/APC3, a component of the APC/C, as a novel molecular target of curcumin and
showed that curcumin binds to and crosslinks Cdc27 to affect APC/C function. We further provide evidence that
curcumin preferably induces apoptosis in cells expressing phosphorylated Cdc27 usually found in highly
proliferating cells.
Conclusions: We report that curcumin directly targets the SAC to induce apoptosis preferably in cells with high
levels of phosphorylated Cdc27. Our studies provide a possible molecular mechanism why curcumin induces
apoptosis preferentially in cancer cells and suggest that phosphorylation of Cdc27 could be used as a biomarker to
predict the therapeutic response of cancer cells to curcumin.
Background
Curcumin, or diferuloylmethane, is a hydrophobic poly-
phenol derived from the rhizome of the herb Curcuma
longa. It is better known as the yellow pigment in the
widely used Asian spice turmeric. Recently, curcumin
gained attention as an anti-cancer agent because of its
chemopreventive and chemotherapeutic potential while
having no discernable side effects. Curcumin induces
apoptosis in various tumor cells and can prevent tumor
initiation and growth in carcinogen-induced rodent
models as well as in subcutaneous and orthotopic tumor
xenografts [1-3]. Although it is still not known why cur-
cumin preferentially kills tumor cells, it has been identi-
fied as one of the major natural agents that inhibit
tumor initiation and tumor promotion.
Curcumin inhibits the proliferation of a wide variety
of cancer cells including breast, blood, colon, liver, pan-
creas, kidney, prostate, and skin [1,2]. We and others
have shown that it induces cell death in medulloblas-
toma, the most common pediatric brain tumor [3-5],
and inhibits tumor growth in in vivo medulloblastoma
models [3]. Curcumin has been suggested to selectively
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target tumor cells by affecting signaling pathways that
regulate cell growth and survival and thus preferably
induces apoptosis in highly proliferating cells [6,7].
Accumulating evidence suggests that curcumin-induced
cell death is mediated both by the activation of cell
death pathways and by the inhibition of growth/prolif-
eration pathways [6,7]. Cell cycle regulatory proteins
and checkpoints are downstream elements of cellular
signaling cascades crucial for cell proliferation. Curcu-
min exerts various effects on cell cycle proteins and
checkpoints, including p53, cyclin D1, cyclin dependent
kinases (CDK), and CDK inhibitors (CDKi) such as
p16INK4a, p21WAF1/CIP1, and p27KIP1 [8]. It most often
induces G2/M arrest, although G0/G1 arrest has been
found in some cells [7]. It is well accepted that a pro-
longed arrest in G2/M phase leads to apoptotic cell
death [9,10]. However, how curcumin induces G2/M
arrest is not well understood.
The mitotic checkpoint, also known as the spindle
assembly checkpoint (SAC) is the major cell cycle con-
trol mechanism in mitosis and delays the onset of ana-
phase until each single kinetochore has become attached
to the mitotic spindle [10]. At the molecular level, the
SAC is a signaling pathway consisting of multiple com-
ponents that communicate between local spindle attach-
ment and global cytoplasmic signaling to delay
segregation. One of the key regulators of the SAC is the
anaphase promoting complex/cyclosome (APC/C), an
E3 ubiquitin ligase. In humans, the APC/C is a multi-
protein complex consisting of at least 12 different subu-
nits that requires other cofactors for proper functioning;
a ubiquitin-activating (E1) enzyme, a ubiquitin-conjugat-
ing (E2) enzyme and co-activator proteins Cdc20 or
Cdh1 [11,12]. Upon activation, APC/C ubiquitinates
cyclin B and securin and targets them for destruction by
proteolysis allowing for mitotic exit [11,12]. However,
APC/C is not only a major effector of the SAC that
ensures cell cycle arrest upon spindle disruption but it
also promotes cell death upon prolonged mitotic arrest
[10]. Thus, APC has become an attractive drug target to
control the growth and proliferation of cancer cells and
facilitate their apoptotic death.
Curcumin has a diverse range of molecular targets,
including thioredoxin reductase, cyclooxygenase-2
(COX-2), protein kinase C, 5-lipoxygenase (5-LOX), and
tubulin [6], supporting the concept that it may act upon
numerous biochemical and molecular cascades. One
interesting feature of curcumin is its ability to crosslink
proteins such as the cystic fibrosis chloride channel
(CFTR) thereby activating the channel [13]. In this
study, we provide evidence that Cdc27, a component of
the APC/C is a novel target for curcumin and that cur-
cumin binds and crosslinks Cdc27. We also show that
curcumin inhibits APC/C activity suggesting that
curcumin binding to Cdc27 might play an important
role in prolonged G2/M arrest induced apoptosis. In
addition, curcumin preferentially induced apoptosis in
cells progressing through G2/M and expressing phos-
phorylated Cdc27 usually found in highly proliferating
cells. Thus, our studies reveal that the SAC is a molecu-
lar target of curcumin and, in addition, provide a possi-
ble explanation for why curcumin preferably induces
cell death in cancer cells as previously reported [6,7].
Methods
Cell lines and reagents
All cell lines were obtained from the American Type
Culture Collection (ATCC, Manassas, VA) and cultured
according to ATCC protocols. The human medulloblas-
toma cell line DAOY was cultured in MEM supplemen-
ted with 10% fetal bovine serum, glutamine and
penicillin/streptomycin in a humidified, 5% CO2 atmo-
sphere at 37°C.
Antibodies against a-tubulin, acetylated a-tubulin,
cleaved caspase3, cleaved PARP, GAPDH, cyclin A, and
cyclin D1 and horseradish peroxidase (HRP)-conjugated
secondary antibodies were obtained from Cell Signaling
Technology (Danvers, MA), APC2, APC7, and APC8 from
Biolegend (San Diego, CA) and Cdc27, Cdc20, BubRI, and
b-actin from BD Transduction Laboratories (Franklin
Lakes, NJ). Antibody against cyclin B1 was purchased
from Santa Cruz Biotechnology (Santa Cruz, CA) and
securin from Abcam (Cambridge, MA). Cdh1 and cyclin E
antibodies, curcumin and half-curcumin (dehydrozinger-
one, DHZ, 4-(4-hydroxy-3-methoxyphenyl)-3-buten-2-
one) were purchased from Sigma-Aldrich (St. Louis, MO).
Cytotoxicity assay
Lactate dehydrogenase (LDH) levels as a measure of cell
death were determined using the Non-radioactive Cyto-
toxicity kit (Promega, Madison, WI) according to manu-
facturer’s instructions. LDH release was determined from
curcumin-treated and untreated control cells grown on
24-well plates by collecting growth medium. Cell debris
was removed by centrifugation. Viable cell LDH was col-
lected from cells lysed by freezing for 15 min at -70°C fol-
lowed by thawing at 37°C. The medium was collected and
cleared from cell debris by centrifugation. The relative
release of LDH was determined as the ratio of released
LDH versus total LDH from viable cells.
Immunoblotting, immunoprecipitations, and l-
phosphatase treatment
Cell lysates were prepared in a buffer containing 20 mM
Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 0.1% Triton X-100, 2.5 mM sodium pyropho-
sphate, 1 mM b-glycerolphosphate, 1 mM sodium vana-
date, 1 mM phenylmethylsulfonyl fluoride and 5 μg/ml
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of antipapain, leupeptin and pepstatin (protease inhibi-
tor cocktail). Protein concentrations were determined by
the Dc protein assay (Bio-Rad, Hercules, CA). Equal
amounts of protein were resolved by SDS-PAGE and
transferred to nitrocellulose. The membranes were
blocked in 5% non-fat milk in Tris-buffered saline with
0.1% Tween-20 (TBST). Primary antibodies diluted in
5% bovine serum albumin/TBST were incubated over-
night at 4°C and HRP-conjugated secondary antibodies
in 5% non-fat milk/TBST for 2 h at room temperature.
Protein bands were visualized by Enhanced Chemilumi-
nescene Plus (GE Healthcare, Piscataway, NJ).
For immunoprecipitation, cells were lysed at 4°C for
30 min in a buffer of 50 mM HEPES, pH 7.4, 150 mM
NaCl, 0.5% NP-40, 1 mM EDTA, 1 mM Na3VO4, 1 mM
aprotinin, 1 mM leupeptin and 1 mM PMSF. Equal
amounts of protein (from 0.5 to 2 mg) were incubated
with Cdc27 antibody for 4 h at 4°C followed by protein
G-sepharose (GE Healthcare) for 2 h, washed exten-
sively, and analyzed by immunoblotting with indicated
antibodies. For l-phosphatase treatment, Cdc27 was
immunoprecipitated as above except that phosphatase
and protease inhibitors were omitted and then incubated
with l - phosphatase according to the manufacturer’s
protocol (New England Biolabs, Ipswich, MA).
Cell cycle analysis
Interphase DAOY cells were treated with curcumin for
indicated times, trypsinized, and fixed in cold 70% etha-
nol. DNA was stained with 100 μg/ml propidium iodide
(PI) in hypotonic citrate buffer with 20 μg/ml ribonu-
clease A. Stained nuclei were analyzed for DNA-PI
fluorescence using an Accuri C6 flow cytometer (Accuri
Cytometers Inc., Ann Arbor, MI). Resulting DNA distri-
butions for sub G0/G1, G0/G1, S and G2/M phase of
the cell cycle were analyzed with CFlow plus software
(Accuri Cytometers Inc).
For analysis of cell cycle profiles after mitotic block,
cells were synchronized with 2 mM thymidine for 24 h.
The block was released for 3 h and cells were arrested
in prometaphase with 100 nM nocodazole for 12 h,
resulting in approximately 70% of the cells arrested in
G2/M. For G1/S arrest, cells were synchronized for 18 h
with 2 mM thymidine, released for 9 h, followed by a
second thymidine arrest for 18 h, resulting in a G1/S
block in about 50% of the cells. The block was then
released in the presence of DMSO or curcumin as indi-
cated and the cells were processed as described above.
In vitro APC assay
In vitro APC assays were performed as described [14]
using an in vitro transcribed and translated N-terminal
fragment of cyclin B1 (cyclin B1-N1-102) as substrate.
35S-methionine labeled cyclin B1-N1-102 was obtained
using the TNT quick-coupled Transcription/Translation
system (Promega, Madison, WI). Cell pellets of control
and curcumin-treated DAOY cells were snap frozen in
liquid nitrogen. The cell pellets were resuspended in an
ice-cold hypotonic buffer (20 mM Hepes pH 7.6, 20
mM NaF, 1.5 mM MgCl2, 1 mM DTT, 5 mM KCl, 20
mM b-glycerophosphate, 250 μM NaVO3, 1 mM PMSF,
and EDTA-free protease inhibitors) and incubated for
30 min on ice. The lysates were briefly homogenized
and cleared by a 1 h centrifugation at 13,000 rpm in a
micro centrifuge. For the assay, 30 μg of total protein
were added to reaction buffer containing 20 mM Tris
pH 7.5, 20 mM NaCl, 5 mM MgCl2, 5 mM ATP-g-S, 20
μg/ml MG-132, 0.5 μg UbcH10, 20 μM ubiquitin, 1 μm
ubiquitin aldehyde, protease inhibitors, and 2 μl of in
vitro translated35S-cyclin B1-N1-102 and incubated at 37°
C for 60 min. The reactions were stopped by adding
sample buffer and proteins were separated by SDS-
PAGE on a 4-15% gradient gel. To visualize the bands,
the gel was incubated and enhanced with salicylate,
dried, and then subjected to autoradiography.
Immobilization of curcumin on epoxy-activated
Sepharose 6B
Curcumin was coupled to epoxy-activated Sepharose 6B as
previously described [15]. Briefly, 20 mM curcumin dis-
solved in coupling buffer (50% dimethylformamide/0.1 M
Na2CO3/10 mM NaOH) was incubated with swollen
epoxy-activated Sepharose 6B beads overnight at 30°C.
After washing, unoccupied binding sites were blocked
with 1 M ethanolamine by overnight incubation. Low (0.1
M acetate buffer, pH 4) and high (0.1 M Tris-HCl, pH 8,
0.5 M NaCl) pH buffers were used each three times to
wash and equilibrate the beads. Control beads were pre-
pared in parallel with curcumin-coupled beads but curcu-
min was omitted. DAOY cell lysates were prepared in a
lysis buffer of 100 mM HEPES, pH 7.6, 300 mM NaCl,
0.1% Triton X-100, 2 mM EDTA, 2 mM EGTA supple-
mented with phosphatase and protease inhibitors. 500 μg
of protein was mixed with 20 μl of curcumin-coupled
Sepharose beads and incubated for 3 h at 4°C. After wash-
ing bound proteins were eluted with 1× SDS-PAGE sam-
ple buffer and processed for immunoblotting.
Statistical analysis
Data are presented as mean ± SD unless otherwise indi-
cated. The differences between means of two groups
were analyzed by a two-tailed unpaired Student’s t-test.
When required, P values are stated in the figure legends.
Results
Curcumin induced cell death is cell cycle dependent
Curcumin can arrest cell-cycle progression and induce
apoptosis in various cancer cells [7]. We and others
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reported previously that curcumin induces G2/M arrest
and apoptosis in medulloblastoma cells [3-5]. We
further found that DAOY medulloblastoma cells
released from a G1/S block in the presence of curcumin
progressed much slower through the cell cycle com-
pared to vehicle-treated control cells (Figure 1A and
Additional file 1: Table S1). While most control cells
reached G2/M 8-12 h after release and almost all of G1/
S blocked cells re-entered G0/G1 after 16 h, cells
released in the presence of 10 and 20 μM curcumin
reached G2/M only after 12-16 and 16-20 h, respec-
tively. In addition, 56.9% of the cells released in the pre-
sence of 20 μM curcumin had not re-entered G0/G1
even 20 h after removal of the thymidine block. How-
ever, no sub-G0/G1 signal was detected indicating that
although the cells were delayed in mitosis they did not
undergo apoptosis within this time frame (Figure 1A).
We also arrested DAOY cells in G2/M by thymidine/
nocodazole treatment and released the block in the pre-
sence or absence of curcumin (Figure 1Band Additional
file 2: Table S2). While 70.2% of the cells were blocked
in G2/M, 36.8% of control cells exited mitosis within 2
hours of release and by 6 h 76.9% had exited G2/M. In
the presence of 10 μM curcumin mitotic exit was signif-
icantly delayed and after 2 and 6 hours 91.5% and 47.7%
of the cells, respectively, remained in G2/M. This effect
was much more pronounced in the presence of 20 μM
curcumin when after 10 h of release still 69.8% of the
cells were found in G2/M. At the same time a signifi-
cant amount of cells was in the sub-G0/G1 fraction sug-
gesting that curcumin-induced delay from G2/M exit
may commit the cells to undergo apoptosis. Together
these data suggest that the sensitivity of DAOY cells to
curcumin-induced cell-death might be cell-cycle depen-
dent. Indeed, DAOY cells treated with 20 μM curcumin
in G2/M were 3-fold more sensitive to curcumin-
induced cell death than cells arrested in either G1/S or
unsynchronized control cells (Figure 1C). Thus, curcu-
min may affect the function of proteins directly involved
in G2/M progression to ultimately induce cell death.
Curcumin binds to the Cdc27/APC3 subunit of APC/C
To test whether curcumin affects known regulators of
mitosis, we analyzed the expression of various cell cycle
proteins in control and curcumin-treated DAOY cells.
We found no noticeable changes in cyclin A and E that
are major players in S-phase and G1/S transition,
respectively. Also, the levels of APC2, an APC/C subunit
essential for ubiquitination, or the APC/C co-activator
p55Cdc20 were comparable in control and curcumin-
treated cells (Figure 2A). Interestingly, immunoblots of
Cdc27 revealed a high molecular weight (MW) band in
curcumin-treated cells that was approximately double
the MW of Cdc27 and its intensity increased with
increasing curcumin concentrations (Figure 2B). This
effect seemed to be specific for Cdc27 since a MW shift
of APC7 or APC8 that both, like Cdc27/APC3, have
TPR domains (Figure 2C), was not detectable. It has
been shown that curcumin can affect a protein’s func-
tion by direct cross-linking [13]. Thus, we tested
whether curcumin could bind directly to Cdc27. Indeed,
curcumin-bound sepharose beads from two independent
preparations pulled down Cdc27 while it was barely
detected with control beads (Figure 3A). In addition,
half-curcumin which has only one b-diketone moiety
and does not have cross-linking capacity [13], failed to
induce the high MW bands of Cdc27, further suggesting
that curcumin indeed induces the formation of Cdc27
dimers (Figure 3B). Interestingly, half-curcumin also
failed to induce cell death in DAOY cells (Figure 3C)
indicating that cross-linking of Cdc27 may be an essen-
tial step in curcumin-induced apoptosis in these cells
(Figure 3C).
In addition, we consistently observed decreased levels
of non-crosslinked Cdc27 in curcumin-treated cells (Fig-
ure 3B and data not shown). We recently showed that
curcumin increases survival in Smo/Smo mice, a trans-
genic medulloblastoma mouse model, and reduces
tumor growth of DAOY xenografts [3]. Interestingly, we
found that in tumors from curcumin-treated mice, the
Cdc27 levels were reduced (Additional file 3: Figure S1
and our unpublished data) when compared with control
mice. However, we were not able to detect the high
MW Cdc27 characteristic for crosslinking, which could
be due to the lower Cdc27 levels found in these tumors
per se. Nevertheless, it suggests the possibility that cur-
cumin targets Cdc27 in vivo to reduce tumor growth.
Cdc27 phosphorylation sensitizes tumor cells to curcumin
In pull-down assays we observed that curcumin seemed
to have a higher affinity for the 130 kDa form of Cdc27
(Figure 3A, upper band). As reported earlier, this MW
is consistent with the phosphorylated form of Cdc27
which we confirmed by l-phosphatase treatment (Addi-
tional file 4: Figure S2). To test whether phosphorylation
of Cdc27 is associated with increased sensitivity to cur-
cumin-induced cell death, we first screened several cell
lines for Cdc27 phosphorylation (Figure 4A). Interest-
ingly, only in cell lines with the phosphorylated form of
Cdc27 was curcumin able to crosslink Cdc27 (Figure
4B) further confirming that curcumin dimerizes prefer-
entially phosphorylated Cdc27. We then chose six of
these cell lines with high (DAOY, HCT116), intermedi-
ate (RT4, NT2) and low (HT1376, MDCK) levels of
phosphorylated Cdc27 and tested their sensitivity to cur-
cumin-induced cell death. As expected DAOY cells were
most sensitive to curcumin-induced apoptosis while
MDCK and HT1376 cells were almost unaffected
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Figure 1 Curcumin induced cell cycle arrest in medulloblastoma cells. A, DAOY cells were arrested in G1/S and the block was released in
the presence of 0, 10 or 20 μM curcumin. At indicated time points cell cycle progression was analyzed by flow cytometry. B, Mitotically arrested
DAOY cells were released from their block in the presence of 0, 10 or 20 μM curcumin. Cell cycle profiles were determined at the indicated time
points. C, Unsynchronized cells were treated with indicated concentrations of curcumin for 12 h. G1/S-arrested DAOY cells were released from
their block for 12 h in the presence of curcumin. To obtain G2/M arrested cells, DAOY cells were synchronized first at G1/S. The block was
released for 8 h in the absence of any drugs. Cells were then treated with the indicated concentration of curcumin for an additional 12 h. The
cell-cycle dependent cytotoxicity of curcumin was measured by an LDH assay. A-C, The data are the mean ± SEM of three independent
experiments.
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(Figure 4C, D; Additional file 5: Figure S3), suggesting
that curcumin preferentially induces apoptosis in cells
with high levels of Cdc27 phosphorylation.
Curcumin inhibits APC activity
Many APC/C components are phosphorylated during
mitosis, which seems to be required for APC/C activity
[16,17]. To test whether cross-linking of Cdc27 by cur-
cumin compromises APC/C activity, we arrested DAOY
cells in G2/M and released the block in the absence or
presence of curcumin. Release of the mitotic block in
DMSO-treated control cells resulted in the dephosphor-
ylation of Cdc27 over time which was not observed in
curcumin-treated cells (Figure 5A). In addition,
Figure 2 Curcumin-induced effects on APC/C and other cell cycle related proteins. A, Expression of the APC/C subunit APC2, the APC/C
co-activator p55Cdc20 and cyclins A and E in control and curcumin-treated DAOY cells as determined by immunoblotting. GAPDH levels are
included to ensure equal loading. B, Immunoblot of the APC/C subunit Cdc27 showing a curcumin-induced shift in MW (arrows) in
unsynchronized DAOY cells. Because of differences in band intensity the same immunoblot is shown with two different exposures. Arrowhead
and asterisk indicate the non-phosphorylated and phosphorylated bands of Cdc27, respectively C, Comparison of MW shift by curcumin
between Cdc27 and other APC components. Tubulin was used for equal loading control.
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decreases in the cyclin B1 and securin levels that are a
prerequisite for mitotic exit were not found in curcu-
min-treated cells but were readily observed in control
cells (Figures 5A, B). In contrast, no significant differ-
ences were found in the levels of the core APC/C subu-
nit APC2, the APC/C coactivator p55Cdc20 or cyclin
D1 in control and curcumin-treated cells (Figures 5A,
B). Together, these data suggest that curcumin might
directly affect the function of the APC/C.
Proper APC/C function requires co-activator proteins
such as Cdc20 or Cdh1 that may facilitate the
recruitment of substrates. Co-immunoprecipitation ana-
lysis in DAOY cells released from a G2/M block in the
presence of curcumin showed that p55Cdc20 association
with Cdc27 was dramatically reduced compared to con-
trol cells while the Cdc27 association with the APC/C
subunits APC2 and APC8 was not affected (Figure 5C).
Under the experimental conditions used we did not find
Cdh1 associating with Cdc27 (Figure 5C). We next
tested whether curcumin affects the activity of APC/C
using an in vitro APC assay that monitors APC’s ubiqui-
tin ligase activity on cyclin B as described earlier [14].
Figure 3 Curcumin associates with Cdc27. A, DAOY cell lysates were incubated with curcumin-bound sepharose beads and then subjected to
SDS-PAGE and immunoblotting with Cdc27. A BubR1 immunoblot was included as control for non-specific binding. B, DAOY cells were
incubated with either curcumin or half-curcumin for indicated time points. Cell lysates were separated by SDS-PAGE and immunoblotted for
Cdc27. The middle panel shows a longer exposure of the same blot in the upper panel. C, LDH release as a measure of cytotoxicity of curcumin
and half-curcumin in DAOY cells treated for 16 h. Data represent mean ± SEM of three independent experiments.
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The cells were arrested in G2/M and released from the
block in the presence or absence of curcumin. Com-
pared to cells blocked at G2/M (Figure 5D), we found a
gradual increase of APC activity upon block release in
control cells indicating that these cells were exiting
mitosis. In contrast, in curcumin-treated cells the APC
activity was reduced 2 hours after block release when
compared to cells after one hour of release indicating
that curcumin inhibits APC activity directly. Together
these data suggest that cross-linking of Cdc27 by curcu-
min reduces its association with its co-activator
p55Cdc20 thus inhibiting APC activity.
Discussion
In recent years many targets of curcumin have been
identified, but the molecular mechanism how curcumin
induces cell cycle arrest at G2/M remains elusive. In
this study, we provide evidence that curcumin could
directly target the SAC to inhibit progression through
mitosis. We show that curcumin binds to and crosslinks
Cdc27, a component of the APC/C and critical for its
function. Consistent with this, we found that curcumin
inhibits APC/C activity thereby preventing the degrada-
tion of cyclin B1 and securin, consequently inducing
G2/M arrest. Furthermore, curcumin appeared to have a
greater affinity for phosphorylated Cdc27, which is
usually found in mitotically active cells. Cell lines that
had little or no phosphorylated Cdc27 thus were less
sensitive to curcumin-induced apoptosis. These results
could provide an explanation why cancer cells are more
sensitive than normal cells to curcumin-induced cell
death and suggest that phosphorylated Cdc27 might
have the potential to be developed as biomarker for
effective curcumin-based therapy in cancer.
Curcumin crosslinks the APC subunit cdc27
Curcumin affects a multitude of molecular targets
including transcription factors, receptors, kinases,
Figure 4 Cdc27 phosphorylation sensitizes tumor cells to curcumin. A, Immunoblot of Cdc27 in various cell lines, DAOY, NT2, D283 Med,
D341 Med (brain); HCT116 (colon); HT1376, RT4 (bladder); MDCK (kidney). The arrow indicates the band corresponding to phosphorylated Cdc27
and arrowhead shows unphosphorylated Cdc27. Actin immunoblot is shown as loading control. B, Cdc27 immunoblot of cell lines in (A) after
treatment with 20 μM curcumin for indicated times. Arrows indicate crosslinked Cdc27, while arrowheads show phosphorylated Cdc27. Equal
amounts of protein were used as shown by actin immunoblot. C, Cytotoxicity of curcumin in six different cell lines with different Cdc27
phosphorylation levels. LDH release was determined after 24 h of exposure to curcumin at indicated concentrations. Data are the mean ± SEM
of three independent experiments. D, Immunoblots of cleaved PARP and caspase-3 as indicators of apoptosis upon exposure to 20 μM
curcumin. Tubulin immunoblot ensures equal amounts of protein being used for analysis. Arrows indicate cleaved PARP.
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Figure 5 Curcumin inhibits APC/C activity. A, DAOY cells were released from thymidine/nocodazole block in the presence of 0, 20 and 40 μM
curcumin for indicated time points. Cell lysates were subjected to immunoblotting with antibodies shown. Arrow indicates phosphorylated
Cdc27, while the arrowhead shows unphosphorylated Cdc27. B, Mitotically arrested DAOY cells were released with different concentrations of
curcumin for 2 and 4 h, respectively, and blotted with antibodies indicated. C, DAOY cells were synchronized by double thymidine arrest and
then incubated with curcumin for 8 h. Cell lysates were subjected to immunoprecipitation with anti-Cdc27 antibodies. Immunoprecipitated
proteins were immunoblotted with antibodies indicated. Immunoblots of total cell lysates are shown to ensure equal loading D, Mitotically
arrested DAOY cells were released in the presence of either DMSO or curcumin for indicated time points and APC/C activity was determined as
described in Materials and Methods.
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inflammatory cytokines, and other enzymes (for a com-
prehensive review see [18]). It modulates multiple sig-
naling pathways including pathways involved in cell
proliferation (cyclin D1, c-myc), cell survival (Bcl-2, Bcl-
xL, cFLIP, XIAP, c-IAP1), and apoptosis (caspase-8, 3,
9). Other pathways affected by curcumin include those
comprising protein kinases (JNK, Akt, AMPK), tumor
suppressors (p53, p21), death receptors (DR4, DR5),
mitochondrial pathways and endoplasmic reticulum
stress responses. Curcumin has also been shown to alter
the expression and function of COX2 and 5-LOX at the
transcriptional and post-translational levels. Thus, it is
possible that many of the cellular and molecular effects
observed in curcumin treated cells might be due to
downstream effects rather than direct interactions with
curcumin.
Although there are now a multitude of studies on cur-
cumin’s cellular effects, surprisingly little is known
about the direct interactions of curcumin with its target
molecules. One of the better characterized interactions
is the binding of curcumin to CFTR [13]. Curcumin can
crosslink CFTR polypeptides into SDS-resistant oligo-
mers in microsomes and in intact cells. However, the
ability of curcumin to rapidly and persistently stimulate
CFTR channels was unrelated to the crosslinking activ-
ity. Interestingly, we found that curcumin can bind to
Cdc27 in vitro and can crosslink Cdc27 in a variety of
cell lines. While CFTR channel activation was unrelated
to the cross-linking of CFTR, we found evidence that
crosslinking of Cdc27 by curcumin appeared to affect
Cdc27 functions itself; half-curcumin neither crosslinked
Cdc27 nor induced apoptosis in DAOY cells.
However, at this point it is not known how curcumin
crosslinks Cdc27 and affects its function. Bernard [13]
suggested that curcumin possibly reacts with the CFTR
through an oxidation reaction involving the reactive b-
diketone moiety. Since half-curcumin that has only one
b-diketone moiety did not crosslink CFTR, the authors
further concluded that the symmetrical structure of cur-
cumin is required for crosslinking and that crosslinking
might occur within one CFTR molecule. Similarly, we
found that half-curcumin failed to crosslink Cdc27 indi-
cating that Cdc27 crosslinking also requires the symme-
trical structure of curcumin. Interestingly, increasing
evidence suggests that Cdc27 exists as a homo-dimer
within APC/C and that this dimerization is essential for
its function. It is possible that curcumin chemically
crosslinks dimerized Cdc27 within the APC complex,
thus interfering with its function.
While curcumin was able to bind to both unpho-
sphorylated and phosphorylated Cdc27, we observed
that only cells expressing phosphorylated Cdc27 showed
the shift to the high molecular weight Cdc27. In addi-
tion these cells were more susceptible to curcumin
induced cell death. It is possible that phosphorylation
induces conformational changes that are more permis-
sive for curcumin binding and/or crosslinking of the
protein and thus curcumin is more effective in these
cells. Cdc27 is one of the five APC subunits with tetra-
trico-peptide repeats (TPR). Nevertheless, we did not
find any crosslinking of other APC subunits with the
TPR motif, suggesting that curcumin crosslinking is spe-
cific to Cdc27. Thus, identification of curcumin’s bind-
ing motifs will not only be important to understand
curcumin’s biological roles but also will be a major step
in developing more specific and effective curcumin ana-
logs for therapy.
Curcumin impedes the interaction of Cdc27 and the APC/
C activator p55Cdc20
Cdc27 is considered as a core component of the APC/C
that secures the interaction with substrate/coactivator
complexes [19]. It directly binds activator subunits such
as p55Cdc20 or cdh1 and associates with mitotic check-
point proteins including Mad2 and BubR1 [20]. Consis-
tent with a role of Cdc27 in controlling the timing of
mitosis and the notion that curcumin-mediated cross-
linking of Cdc27 impairs its function, we observed a
delay in the mitotic exit in curcumin-treated cells when
compared to control cells. It is thought that the SAC
acts by inhibiting the p55Cdc20-bound form of the
APC/C and that repression of APC/C stabilizes its
downstream targets including cyclin B and securin
[11,21]. We not only found that curcumin treatment
blocked cyclin B1 and securin degradation but also
observed a decreased association of p55Cdc20 with
Cdc27 under these conditions. At the same time, asso-
ciation of Cdc27 with other subunits of the APC/C such
as APC2 and APC8 did not change (Figure 5C). Thus,
we suggest that curcumin might repress APC/C function
by preventing the efficient association of the APC/C
core complex with its activator p55Cdc20.
APC/C is partially activated through phosphorylation
of core subunits. Cdc27 undergoes mitosis-specific
phosphorylation [22,23] which seems to enhance the
affinity between APC/C and p55Cdc20 thereby ensuring
its activation [24-27]. Analysis of mitosis-specific phos-
phorylation sites in Cdc27 revealed that most of them
are clustered in confined regions, mainly outside of the
TPR repeats [25]. We found that curcumin specifically
crosslinks Cdc27 and not other APC/C subunits with
TPR motifs. We also noticed that curcumin preferably
binds to phosphorylated Cdc27 and induces apoptosis
more effectively in mitotic cells. At this point we do not
know how curcumin prevents p55Cdc20 binding to
Cdc27. It is possible that curcumin blocks the phos-
phorylated interaction sites directly or that curcumin
crosslinking induces a conformational change in Cdc27
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that is less permissive to p55Cdc20 binding. It is also
conceivable that curcumin binding to Cdc27 itself pre-
sents a steric hindrance for p55Cdc20 to access its bind-
ing sites. Whatever the mechanism, curcumin’s
interaction with mitotic phosphorylated Cdc27 might
provide a possible explanation why curcumin preferen-
tially induces cell death in tumor cells that are usually
highly proliferative and not in normal cells [6,7].
Curcumin-treatment induces tubulin acetylation
Curcumin has been reported to bind to tubulin, inhibit
tubulin polymerization in vitro, depolymerize interphase
and mitotic microtubules in HeLa and MCF-7 cells, and
suppress the dynamic instability of microtubules in MCF-7
cells [28,29]. Microtubules form the mitotic spindle during
cell division and because of the rapid assembly and disas-
sembly of microtubules during the alignment and separa-
tion of chromosomes, spindle microtubules are highly
dynamic [30]. We recently reported that mitotic spindle
tubules in curcumin treated DAOY cells were disorganized
and showed increased staining, suggestive of microtubule
stabilization [3]. We also found that curcumin treatment
increased tubulin acetylation in these cells. While the exact
function of tubulin acetylation has not yet been determined,
it is usually associated with increased microtubule stability
[31]. Because of the discrepancies of the role of curcumin
in tubulin depolymerization in interphase cells and tubulin
stabilization in mitotic cells we had previously suggested
that factors other than direct binding of curcumin to tubu-
lin might contribute to the altered mitotic spindle organiza-
tion in curcumin-treated cells [3]. Interestingly, it has been
reported recently that p55Cdc20 interacts with histone dea-
cetylase (HDAC) 6 [32]. HDAC6 can associate with micro-
tubules and deacetylate a-tubulin [33]. At this point, we do
not know whether there is a connection between reduced
binding of p55Cdc20 to curcumin-crosslinked Cdc27,
HDAC6 function, and tubulin acetylation. However, we
found that in cells with low levels of phosphorylated Cdc27
in which curcumin failed to cross-link Cdc27 and that were
less sensitive to curcumin treatment, curcumin-induced
tubulin acetylation was also reduced (Additional file 6: Fig-
ure S4). Thus, loss of Cdc27 function or p55Cdc20 associa-
tion with Cdc27 might be linked to increased tubulin
acetylation in curcumin-treated cells.
Cell cycle exit as a target for cancer therapy
The mitotic spindle is a validated target for cancer thera-
peutics. While antimitotic agents that target the mitotic
spindle (such as vinca alkaloids, taxanes, and epothilones)
are widely used in the clinic for the treatment of human
malignancies they exhibit serious side-effects due to their
effects on microtubule function in normal cells. In addi-
tion, upon activation of the SAC by a non-functional mito-
tic spindle, cells do not arrest in G2/M indefinitely. After
an extended time of mitotic arrest, cells either die in mito-
sis by apoptosis or leak through the SAC by adaptation or
mitotic slippage [9] which has been associated with resis-
tance to antimitotic drugs [34]. Thus, blocking mitotic exit
downstream of the checkpoint may be a better cancer
therapeutic strategy than perturbing spindle assembly [35].
Indeed, Huang et al. [35] showed that blocking mitotic
exit by p55Cdc20 knockdown induced cell death and sug-
gested that a small molecule that binds APC/C and com-
petes with the p55Cdc20 binding site might be the most
obvious inhibition strategy. We suggest that curcumin
might be such a small molecule that abrogates APC/C and
p55Cdc20 interaction.
Conclusions
We found that curcumin directly targets the SAC by bind-
ing to Cdc27, one of the core components of APC/C.
Furthermore, we show that curcumin preferentially
induces cell death in cells with phosphorylated Cdc27 and
suggest that Cdc27 phosphorylation could be developed as
a biomarker to identify curcumin-sensitive tumors.
Although the in vivo bioavailability of curcumin is limited,
many nanotechnology approaches are being developed for
efficient curcumin delivery [1,36-38] and curcumin might
prove to be an efficient drug to treat medulloblastoma and
other cancers with minimal side effects.
Additional material
Additional file 1: Table S1. Curcumin blocks mitotic progression of
DAOY cells arrested in G1/S. Quantitative analysis of data in Figure 1A.
Additional file 2: Table S2. Curcumin blocks mitotic progression of
DAOY cells arrested in G2/M. Quantitative analysis of data in Figure 1B.
Additional file 3: Figure S1. Cdc27 levels in Smo/Smo mouse tumors.
Immunoblot of Cdc27 levels in medulloblastoma samples obtained from
Smo/Smo mice treated with curcumin or corn oil as previously
described. Tubulin was shown for equal loading.
Additional file 4: Figure S2. DAOY cells express hyperphosphorylated
Cdc27. Immunoprecipitated Cdc27 was incubated with or without
lphosphatase for indicated time points and then resolved in SDS-PAGE
for Western blotting. Arrowhead indicates phosphorylated Cdc27 and
asterisk indicates IgG of input antibodies.
Additional file 5: Figure S3. Curcumin selectively blocks mitotic
progression in different cell lines. NT2 and MDCK cells were arrested with
thymidine/nocodazole treatment. Cells were washed and then released
from mitotic block with different concentrations of curcumin for
indicated time points. DNA contents were analyzed for cell cycle
progression. Data are expressed as mean ± SEM of three independent
experiments.
Additional file 6: Figure S4. Curcumin-induced acetylated tubulin
accumulation. Accumulation of acetylated tubulin in six different cell
lines that were incubated with 20 μM curcumin for 0, 4, 8 and 24 h.
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